Etsy Inc vs Sana Biotechnology Inc — how do they compare? Etsy Inc trades at $85.51 (market cap $8.14B), while Sana Biotechnology Inc trades at $3.16 (market cap $987.94M). The key difference: Etsy Inc is far larger — about 8.2× Sana Biotechnology Inc's market cap, and Etsy Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| ETSY | SANA | |
|---|---|---|
Market Cap | $8.14B | $987.94M |
Sector | Consumer Cyclical | Health |
52-Week High | $85.74 | $5.92 |
52-Week Low | $44.05 | $2.68 |
Enterprise Value | $9.79B | $962.13M |
Signals from Pluang's Aura AI — not financial advice
ETSY trades at $84.30, up 1.49% today, with a bullish technical signal from moving averages. The stock shows strong earnings beats in recent quarters but faces declining revenue and net income margins year-over-year. Positive sentiment is driven by AI-powered seller tools and app engagement growth, though active buyer declines remain a concern. Cash flow improved significantly in 2025 to $593 million.
Outlook is mixed: analyst consensus is cautious with a $72.38 price target below current levels, but technical momentum and AI initiatives offer upside potential. Key risks include high debt, competitive pressure, and inconsistent profitability. Institutional sentiment leans bullish with 49% buy ratings.
Sana Biotechnology (SANA) trades at $3.225, down 9.66% on the day, reflecting market volatility despite a bullish technical signal and strong analyst support. The company shows significant financial losses with a -$244.17M net income for 2025 and negative cash flows, but has beaten earnings expectations in two of the last three quarters. Recent news highlights clinical progress in cell therapies and a $69M capital raise via an ATM facility in May 2026.
The investment case balances high-risk fundamentals against promising clinical developments and overwhelming analyst optimism. While substantial losses and cash burn present clear risks, the company's scientific advancements and 82% buy rating from analysts suggest potential long-term upside for risk-tolerant investors in the biotech sector.
Trailing returns across standard periods
Latest headlines on both assets
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →